Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

BioScience Health Innovations (BHIC) Income from Continuing Operations (2020 - 2026)

BioScience Health Innovations has reported Income from Continuing Operations over the past 7 years, most recently at 229907.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 153.87% to 229907.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 467683.0 through Mar 2026, down 192.73% year-over-year, with the annual reading at 112061.0 for FY2025, 363.48% up from the prior year.
  • Income from Continuing Operations was 229907.0 for Q1 2026 at BioScience Health Innovations, up from 686698.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 457704.0 in Q2 2025 and troughed at 686698.0 in Q4 2025.
  • The 5-year median for Income from Continuing Operations is 38376.0 (2023), against an average of 21543.71.
  • Year-over-year, Income from Continuing Operations tumbled 1392.18% in 2022 and then soared 899.53% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 28917.0 in 2022, then crashed by 32.71% to 38376.0 in 2023, then tumbled by 37.76% to 52865.0 in 2024, then crashed by 1198.97% to 686698.0 in 2025, then soared by 66.52% to 229907.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Income from Continuing Operations are 229907.0 (Q1 2026), 686698.0 (Q4 2025), and 8782.0 (Q3 2025).